V-Card | Print | PDF | Email Page

Renaud Bonnet

Practice Leader Private Equity


(T) +
(F) +


  • Columbia University (LL.M. 1997; Harlan Fiske Stone Scholar); Université de Paris II-Panthéon Assas (DESS/DJCE in Business Law and Taxation 1994; Double Maîtrise with honors and high honors 1993); ESSEC Graduate School of Management (MBA 1993); Institut d'Etudes Politiques de Paris (Sciences Po) (Diplôme — section Service Public 1991)

Bar Admissions

  • Paris and New York Bars

Renaud Bonnet co-chairs Jones Day's global Private Equity Practice, and his practice areas include venture capital, private equity, M&A, and capital markets. He primarily represents technology and life sciences companies, as well as the private equity and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to multibillion dollar global corporations. He has acted as principal lawyer in a significant number of early to late stage financing rounds, LBO and other M&A transactions, joint ventures, initial public offerings, rights issues, private placements, and tender offers.

Renaud's recent experience includes representations of technology and life sciences companies Adocia, Advicenne, Ansys, Cellectis, Criteo, Devialet, EcoVadis, HRA Pharma, Ivalua, Mauna Kea Technologies, Nanobiotix, Planisware, Prodways, Sigfox, Talend, TxCell, Voltalia, and Voluntis. His recent investor-side representations include: Abingworth, Alven, Bpifrance, Creadev, Danone Ventures, Elaia, Felix Capital, Goldman Sachs, Orange, Hi Inov, Idinvest, Illumina Ventures, Khazana, Seventure, Temasek, and Sofinnova.

Illustrative transactions in which Renaud acted as lead lawyer include: representing the issuer and/or underwriters in more than 100 IPOs and follow-on offerings; the IPOs of Criteo, Cellectis, and Talend on NASDAQ; the tender offers on Completel, Wavecom, Assystem, and TxCell; the LBOs of HRA Pharma by Astorg and Goldman Sachs, Orolia by Eurazeo, A2Mac1 by Five Arrows, and Brico Privé by Florac; the sale of Novexel to AstraZeneca and Synthesio to Ipsos; the acquisition of French technology companies by Autodesk, Criteo, SAP, and Ansys; and the latest financing rounds of Devialet, Ivalua, ManoMano, and Younited.

Renaud is a member of the Consultative Commission on Issuers' Transactions and Financial Information of the French Financial Markets Authority (AMF).

Honors & Distinctions

  • Ranked annually as a leading lawyer for private equity/venture capital, equity capital markets, M&A, and life sciences (Chambers Europe, The Legal 500, Private Equity Magazine, Leaders League)

    "Best Lawyer in France" for venture capital, Best Lawyers®/Les Echos (2018)

    "Private Equity Lawyer of the Year," Option Droit & Affaires (2018)

    First prize for number of capital markets transactions, Le Magazine des Affaires (2017)


English, French
Renaud Bonnet